Dexcom has rebounded since my last update, but I maintain a 'Hold' rating due to continued overvaluation and limited upside potential. Growth remains solid, especially in sensors and U.S. expansion, ...
DexCom’s earnings report for the first quarter of 2025 revealed substantial revenue growth reaching $1.036 billion, a 12% increase reported and a 14% organic rise year-over-year. This marks the second ...
DexCom, Inc. (NASDAQ:DXCM) is one of the best strong buy healthcare stocks to buy now. On July 16, Mizuho analyst Anthony Petrone raised the firm’s price target on DexCom, Inc. (NASDAQ:DXCM) to $100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback